Citadel Advisors
KNSA icon

Citadel Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Citadel Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$568K Sell
11,800
-300
-2% -$13.3K ﹤0.01% 8995
2025
Q4 		$499K Buy
12,100
+3,900
+48% +$156K ﹤0.01% 9017
2025
Q3 		$318K Buy
+8,200
New +$266K ﹤0.01% 10217
2025
Q2 		– Sell
-5,600
Closed -$124K – 13893
2025
Q1 		$124K Buy
5,600
+1,500
+37% +$30.9K ﹤0.01% 11160
2024
Q4 		$81.1K Sell
4,100
-2,300
-36% -$52.5K ﹤0.01% 11767
2024
Q3 		$160K Buy
6,400
+5,500
+611% +$134K ﹤0.01% 10479
2024
Q2 		$16.8K Sell
900
-3,500
-80% -$65.6K ﹤0.01% 12774
2024
Q1 		$86.8K Sell
4,400
-2,200
-33% -$43K ﹤0.01% 11545
2023
Q4 		$116K Sell
6,600
-11,100
-63% -$182K ﹤0.01% 10746
2023
Q3 		$307K Buy
17,700
+15,600
+743% +$263K ﹤0.01% 9112
2023
Q2 		$29.6K Buy
2,100
+1,500
+250% +$20.1K ﹤0.01% 12366
2023
Q1 		$6.46K Sell
600
-700
-54% -$9.22K ﹤0.01% 13804
2022
Q4 		$19.5K Sell
1,300
-19,800
-94% -$288K ﹤0.01% 13167
2022
Q3 		$271K Buy
+21,100
New +$240K ﹤0.01% 9788
2022
Q1 		– Sell
-12,500
Closed -$147K – 14127
2021
Q4 		$147K Sell
12,500
-37,400
-75% -$460K ﹤0.01% 12285
2021
Q3 		$568K Sell
49,900
-14,800
-23% -$193K ﹤0.01% 9564
2021
Q2 		$901K Sell
64,700
-5,800
-8% -$88.1K ﹤0.01% 8628
2021
Q1 		$1.3M Buy
70,500
+51,000
+262% +$1.04M ﹤0.01% 7449
2020
Q4 		$345K Buy
19,500
+5,600
+40% +$98.4K ﹤0.01% 8823
2020
Q3 		$213K Buy
+13,900
New +$261K ﹤0.01% 8705

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Citadel Advisors's KNSA Position: Q1 2026 in Review

Citadel Advisors reduced its Kiniksa Pharmaceuticals (KNSA) stake by 36% in Q1 2026, selling an estimated $11.8M and leaving 474,750 shares worth $22.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2167.

Citadel Advisors first reported a position in KNSA in Q2 2018 and has held it in 32 quarters since. The position peaked at $30.6M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Citadel Advisors held 474,750 shares of Kiniksa Pharmaceuticals worth $22.9M as of Q1 2026.
  • Citadel Advisors sold 267,368 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $11.8M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2167 holding.
  • Citadel Advisors first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
  • Citadel Advisors's Kiniksa Pharmaceuticals position peaked at $30.6M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.